Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “treatment of locally advanced prostate cancer”.
-
Clinical Benefit
Substantial
The actual benefit of ENANTONE is substantial.
Clinical Added Value
no clinical added value
ENANTONE SR 3.75 mg and 11.25 mg, do not improve actual benefit (level V) compared to other GnRH analogues in the treatment of locally advanced prostate cancer.
Listen
